BACKGROUND: Detection of circulating tumor cells (CTC) in breast cancer patients is currently performed in many clinical trials, using different technologies, in particular the EpCAM-dependent CellSearch® system. The purpose of this study was to investigate the incidence and prognostic relevance of viable CTC in a large cohort of metastatic breast cancer (MBC) patients.
detects living CTC and disseminated tumor cells (DTC) in cancer patients (9 ) . This technique is based on the detection of proteins secreted by functional CTC or DTC cells combined with a negative enrichment (leukocyte depletion). This new method allows enumeration of only living CTC. Recently, it has been demonstrated that the majority of circulating breast cancer cells undergo apoptosis (7, 8 ) . However, an efficient metastasis process requires living CTC (10 ) . Thus, in contrast to other CTC technologies, the EPISPOT assay focuses on CTC with the potential to colonize secondary organs such as liver, lung, or bone. Moreover, the EPISPOT assay is a promising tool to identify proteins secreted by CTC or DTC, thereby providing an opportunity to better characterize their intrinsic properties responsible for survival, migration, and colonization of distant organs.
Here, we report the results of the first prospective multicenter study to evaluate the prognostic impact of CTC detection using the EPISPOT assay in parallel with the CellSearch® system (gold standard) in metastatic breast cancer (MBC) patients.
Materials and Methods

PATIENTS
A total of 254 MBC patients from 9 German university breast cancer centers [Düsseldorf (n ϭ 4), Erlangen (30), Essen (46), Freiburg (9) , Hamburg (79), Heidelberg (18) , Munich (16) , Regensburg (2) , and Tuebingen (50)] were enrolled in this prospective open study from December 2007 until April 2009. The median (range) age of the patients was 60 (49 -68) years, and 50% of the patients were over 60 years old. Briefly, 67% of the patients had metastasis in more than 1 site and 14% had metastasis localized in the bone, 39% had visceral metastatic sites, and 47% had both sites (visceral and bone).
The criteria used for patient enrollment were (a) epithelial invasive carcinoma of the breast with metastasis to distant organs (M 1 ), (b) age at least 18 years, (c) first diagnosis of metastatic disease or disease progression (before the start of a new line of therapy), (d) written informed consent, and (e) no secondary primary malignancy. A criterion for exclusion was the presence of a secondary primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).
Patients were treated according to international guidelines, as indicated in the previous publications of the DETECT (Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients) study group (11, 12 ) . All HER2ϩ patients received HER2-targeted therapy (usually trastuzumab) that may indeed have influenced the prognosis of HER2ϩ patients. Hormone receptor-positive patients received endocrine therapy (eventually plus chemotherapy), and hormone receptor-negative patients received chemotherapy.
Blood was collected before the start of a new treatment regimen. Participants gave their consent for the use of their blood samples. Data management was carried out from our databank (11 ) . The local ethics committee approved this analysis (2007/B01). Blood was drawn before the start of a new line of therapy. All patients gave informed consent for the use of their blood samples. A web-based databank was designed for data management and online-documentation (www.detectstudy.de). By the use of this interface, clinical investigators were blinded for test results and the CTC test sites were blinded for the clinical data of the patients. The local institutional review boards approved the conduct of this study (2007/B01).
METHODS
CTC detection. The detection of CTC was performed using both the EPISPOT assay and the CellSearch system (Veridex). CTC analysis by the CellSearch system was performed as described previously (11, 13 ) . Blood samples for the EPISPOT assay were analyzed at the Laboratory of Rare Circulating Human Cells (LCCRH) at the Institute of Research in Biotherapy, UMC, Montpellier, France. The blood samples were sent at room temperature and processed within 24 h.
EPISPOT assay. Preanalytical conditions were determined by spiking experiments with breast cancer cell lines. We observed a decrease in tumor cell viability and number after 24 h at room temperature. Storage at ϩ4°C was less favorable.
The EPISPOT assay was performed in only 194 of the 254 patients because Montpellier joined the DETECT study group after the start of the study and we therefore missed the first blood samples for the EPISPOT analysis and because of the exclusion of blood samples that failed to meet preanalytical quality criteria. These samples included those with less than the required 7.5 mL and those that were received more than 24 h following the blood draw.
The EPISPOT assay was performed from a blood samples of 7.5 mL collected in EDTA tubes. Enrichment of CTC was performed using the RosetteSep human circulating epithelial tumor cell enrichment cocktail (StemCell Technology). The nitrocellulose membranes of the EPISPOT plate were precoated with a defined antibody to target a specific protein, anticytokeratin-19 (CK19) antibody in our study (9, 14, 15 ) . The coating antibody CK19 (clone Ks 19.1, Progen Bio-technik) was diluted in PBS (6 g/mL) and was incubated at 4°C for 12 h. After membrane blocking (100 L of 5% BSA/PBS at 37°C for 2 h), CTC enriched by leukocyte depletion with the RosetteSep human circulating epithelial tumor cell enrichment cocktail (StemCell Technology) were incubated at 37°C (5% CO 2 ) for 18 h in cell line medium [DMEM ϩ GlutaMax (Gibco) with 10% fetal calf serum and penicillin/streptomycin]. Membranes were then washed using PBS/0.1% Tween (6 times) and PBS (3 times). The CK19 proteins released during the cell culture were detected by a second Alexa 555 conjugated anti-CK19 antibody (clone Ks 19.2, 3 g/mL; Progen Biotechnik GMBH). This antibody was diluted in PBS and incubated at 4°C for 12 h. All single protein fingerprints generated CK19 immunospots that were observed and enumerated using video camera imaging and computer-assisted analysis (KS ELISPOT, Carl Zeiss Vision).
CellSearch assay. Blood samples were collected into CellSave tubes (Veridex). The enrichment and enumeration of CTC were carried out using the CellSearch epithelial cell test (Veridex). Briefly, CTC were isolated from peripheral blood by an anti-EpCAM antibody-bearing ferrofluid and all DAPI 
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(ϩ) cells were identified as CTC (4 ) . A blood sample containing at least 5 CTC was considered positive (16 ) .
STATISTICAL ANALYSIS
Associations between categorical variables were examined using 2 tests. Overall median survival was calculated by the Kaplan-Meier method. A time-dependent ROC curve was drawn and a MAX-STAT test was used to determine a CTC threshold for OS and progressionfree survival (PFS). PFS was calculated as described by Müller et al. (11 ) . Log rank tests were used to compare the survival curves by CTC detection groups. Univariate and multivariate Cox proportional hazards regression models were used to obtain unadjusted and fully adjusted hazard ratios and 95% CIs. The Bayesian information criterion (BIC) was used to compare Cox regression models.
Results
CTC DETECTION RATES
The specificity of the EPISPOT assay already had been determined in a group of 25 healthy controls, as reported in our previous publication (15 ) .
CTC expressing EpCAM and/or CK19 were detected in MBC patients using the CellSearch and the EPISPOT assays (Fig. 1) . CTC counts determined by the EPISPOT assay were available for 194 of the 254 patients. Detection of CTC by the EPISPOT assay revealed that 59% (115/194) of patients were positive, whereas only 48.0% (122/254) were positive for CTC detected by the CellSearch assay. These data are summarized in Table 1 .
Comparison of the EPISPOT and CellSearch assays revealed a low agreement between the 2 methods as demonstrated by a low Cohen coefficient of 0.14 (P ϭ 0.0416) ( Table 2) .
Furthermore, we analyzed the combination of both methods in a total of 194 MBC patients. In 76.3% of cases, CTC were detected either by the EPISPOT assay alone (27.4%), or the CellSearch system alone (15.3%) or both methods (33.7%), whereas 23.7% of patients remained CTC negative.
SURVIVAL ANALYSIS RELATED TO CTC RESULTS OBTAINED WITH EPISPOT ASSAY
To evaluate the EPISPOT assay as a predictor of survival, the OS according to the concentrations of CTC detected by the EPISPOT assay was estimated by the Kaplan-Meier method. A time-dependent ROC curve was drawn using the survival and CTC status (EPISPOT assay) of each MBC patient. ROC curve analysis showed that a cutoff value of 1 CTC has the highest sensitivity/specificity to predict OS. Of 194 patients, 115 had Ն1 CK19-releasing CTC (59%) per 7.5 mL of blood. These CTC-positive patients showed a significantly reduced OS compared to patients without CK19-releasing CTC (P ϭ 0.0191, log rank test) ( Fig. 2A) . The median OS of patients without CK19-releasing CTC was significantly longer (5 years; 95% CI, 4.16 -8.91) in comparison with CTC-positive patients (2.8 years; 95% CI, 1.43-7.95). For PFS, no threshold of prognostically relevant CTC counts was identified by the Max-STAT and ROC curve analysis.
SURVIVAL ANALYSIS RELATED TO CTC RESULTS OBTAINED WITH CELLSEARCH ASSAY
In the cohort of 254 MBC patients (DETECT study), the prognostic value of the CellSearch assay has been reported by Müller et al. (11 ) . The median OS was 18.1 months in CTC-positive patients (95% CI 15.1-22.1). The PFS was not found to be correlated to the CTC a Cohen coefficient ϭ 0.14; P ϭ 0.041. counts in this cohort receiving different types of treatments (P ϭ 0.197). In multivariate analysis, we confirmed that the concentrations of CTC were an independent predictor for OS (data not shown).
SURVIVAL ANALYSIS RELATED TO COMBINED EPISPOT AND CELLSEARCH RESULTS
We subsequently compared the prognostic power of the EPISPOT-based CTC detection with that of the CellSearch assay as the only FDA-cleared CTC assay (gold standard). OS was evaluated according to CTC status assessed by the EPISPOT assay, the CellSearch assay and by a combination of both methods. Interestingly, Kaplan-Meier analysis showed that the OS was significantly better in the patients negative for CTC using both methods of detection (Fig. 2B) . Statistical analysis was carried out using the log rank test between CTC double-negative patients and the other 3 groups (EPISPOT positive, CellSearch positive, and double positive). We observed that the survival period was significantly shorter for the 3 groups with at least 1 test positive for CTC in comparison with the double-negative group (Both EPISPOT and CellSearch positive vs double negative, P ϭ 0.0004, log rank test; only EPISPOT positive vs double negative, P ϭ 0.0062, log rank test; only CellSearch positive vs double negative, P ϭ 0.0067, log rank test). Thus, the combination of both CTC technologies was found to enhance the stratification of MBC patients into low-and highrisk groups.
MULTIVARIATE COX ANALYSIS OF OS
The variables (CTC status, HER2, progesterone-and estrogen receptor status, therapeutic setting, and disease-free interval) found to be significant at a 20% threshold in a univariate Cox analysis for OS were included into the multivariate analysis (Table 3) .
Although clinical factors such as HER2 and estrogen receptor status and therapeutic setting (P ϭ 0.0001, P ϭ 0.0364, and P ϭ 0.005, respectively) remained prognostically relevant, the CTC status (EPISPOT and CellSearch method) emerged as the second best independent predictor of OS (P ϭ 0.0211) ( Table 4 ). To determine the best predictor of OS among the 3 CTC detection approaches (i.e., EPISPOT assay, CellSearch system, or combined CellSearch and EPISPOT analyses), we compared them using the BIC method. We observed that the diagnostic approach using both the CellSearch and the EPISPOT results was the best predictor of OS (BIC , 317.650), followed by the EPISPOT (BIC, 346.203) and CellSearch methods (BIC, 435.1).
Discussion
In this prospective multicenter study, the prognostic value of the EPISPOT assay was evaluated according to the concentrations of viable CK19-releasing CTC. We have previously shown that CK19 -although it is a cytoskeleton protein-is released from viable breast can- EPISPOT ϩ CellSearch vs double negative, P ϭ 0.0004 log rank test; EPISPOT vs double negative, P ϭ 0.0062 log rank test; CellSearch vs double negative, P ϭ 0.0067 log rank test.
cer cells and can be used as sensitive and specific marker in the EPISPOT assay (17 ) . CK19 is also the most established and clinically validated marker for breast cancer patients in reverse-transcription PCRbased CTC assays, which detect minute amounts of CK19 mRNA (18 ) .
Using the EPISPOT assay, OS was correlated with the CTC status. In multivariate analysis, the presence of CTC as measured by the EPISPOT assay was not an independent predictor for OS. However, the combination of results from both the CellSearch and EPISPOT systems was a better predictor of OS.
In the DETECT study previously published, no correlation was found between CTC detection and PFS using the CellSearch system. In the study we report here, performed in the same cohort of MBC patients, the CTC status determined by EPISPOT assay was not predictive of PFS either. As suggested by Mü ller et al., this lack of correlation could result from different definitions of disease progression based on institutional standards of the participating centers (11 ) . The correlation between CTC detection and clinical outcome observed in our study suggests that the detected cells are tumor cells. However, circulation of normal epithelial cells under certain pathophysiological conditions may contribute to the pool of cells detected with the EPISPOT or CellSearch assays, as indicated by our previous publication (15 ) . Further molecular characterization of CTC would be the only way to verify whether these circulating CK19-positive cells were of malignant or simply epithelial origin. However, in the EPISPOT assay, cells (including CTC) are washed off before the second antibody set revealed the immunospots. We are presently working on a new generation of EPISPOT in which the CK19-secreting cells can be collected for further molecular analysis.
In peripheral blood of breast cancer patients, the majority of CTC were reported to be apoptotic (7, 8 ) , and after mastectomy the half-life of CTC is estimated to be between 1 and 2.4 h (19 ) . Although CTC undergo high levels of apoptosis in the peripheral blood, we observed that the majority of MBC patients present with viable CTC. However, this rate could be even higher. Due to the heterogeneity of CK expression in breast cancer (20, 21 ) , we may miss viable CK19-negative CTC.
Recent reports have related the high plasticity of CTC to an aggressive phenotype of tumor cells (22, 23 ) . CTC can undergo epithelial-mesenchymal transition (EMT) and the reverse process of mesenchymal-epithelial transition. Epithelial CTC express E-cadherin, Epcam, and certain CKs. During the EMT process, these markers may be completely or partially downregulated in CTC, and expression of mesenchymal proteins such as vimentin and N-cadherin may become upregulated. In the present study, we used only epithelial markers and may have missed CTC with a mesenchymal phenotype. Thus, new markers that are not downregulated during the EMT process are urgently needed. For example, plastin-3, an actin bundling protein, is not repressed during EMT in colorectal cancer and has been recently used as a marker for prognostically relevant CTC of colorectal cancer (24 ) . Plastin-3 is also expressed in other epithelial tumors (including breast cancer) and might, therefore, become a widespread marker for CTC assays. As an alternative, Yu et al. have used a combination of cell surface antigens to capture mesenchymal and epithelial CTC in MBC patients; however, CTC were detected in fewer than 50% of MBC patients (25 ) .
In summary, we found that the majority of MBC patients harbor viable CTC expressing and releasing CK19, and the presence of these tumor cells in the peripheral blood predicts an unfavorable clinical outcome, especially if combined with results of the CellSearch system. These findings highlight the need to develop more functional CTC assays and even to combine CTC assays based on different detection principles to address the problem of intra-and interpatient heterogeneity of CTC in MBC patients. 
